基于血清IL-17细胞表达比例观察解毒化瘀颗粒对乙型肝炎相关性慢加急性肝衰竭预后干预研究

Observation on Prognosis of Jiedu Huayu Granule in Patients with HBV-ACLF Based on the Expression Ratio of Serum IL-17 Cells

目的:基于血清IL-17细胞比例观察解毒化瘀颗粒对乙型肝炎相关性慢加急性肝衰竭(HBV-ACLF)预后的影响。方法:将60例HBV-ACLF患者随机分为治疗组及对照组各30例。对照组给予西医综合治疗,治疗组在对照组基础上辨证予解毒化瘀颗粒。疗程8周,随访2个月。结果:治疗后,治疗组肝功能、总末期肝病模型评分(MELD)和临床症状均优于对照组(P<0.05);治疗组外周血IL-17细胞计数明显低于对照组(P<0.05);治疗组总有效率82.8%,对照组53.6%。结论:中西医结合治疗的临床疗效优于单一西医治疗。解毒化瘀颗粒可以在一定程度上减少患者外周血IL-17细胞的数量,改善肝脏功能,提高生存率。

Objective:Effect of Jiedu Huayu Granule on the prognosis of HBV-ACLF based on the ratio of serum IL-17 cells.Methods:Sixty patients with HBV-ACLF were randomly divided into treatment group and control group,30 cases each.The control group was given comprehensive treatment of Western medicine,the treatment group was given Jiedu Huayu Granule on the basis of the control group.The course of treatment was 8 weeks and followed up for 2 months.Results:After treatment,the liver function,MELD and clinical symptoms of the treatment group were better than the control group(P<0.05);The number of IL-17 cells in the peripheral blood of the treatment group was significantly lower than the control group(P<0.05);The total effective rate of the treatment group was 82.8%,and the control group was 53.6%.Conclusion:The clinical efficacy of integrated Chinese and Western medicine treatment is better than single Western medicine treatment.Jiedu Huayu Granule can reduce the number of IL-17 cells in peripheral blood of patients to a certain extent,improve liver function and improve survival rate.